Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment.

European Heart Journal
Roberto FerrariKim M Fox

Abstract

Chronic stable angina is the most prevalent symptom of ischaemic heart disease and its management is a priority. Current guidelines recommend pharmacological therapy with drugs classified as being first line (beta blockers, calcium channel blockers, short acting nitrates) or second line (long-acting nitrates, ivabradine, nicorandil, ranolazine, and trimetazidine). Second line drugs are indicated for patients who have contraindications to first line agents, do not tolerate them or remain symptomatic. Evidence that one drug is superior to another has been questioned. Between January and March 2018, we performed a systematic review of articles written in English over the past 50 years English-written articles in Medline and Embase following preferred reporting items and the Cochrane collaboration approach. We included double blind randomized studies comparing parallel groups on treatment of angina in patients with stable coronary artery disease, with a sample size of, at least, 100 patients (50 patients per group), with a minimum follow-up of 1 week and an outcome measured on exercise testing, duration of exercise being the preferred outcome. Thirteen studies fulfilled our criteria. Nine studies involved between 100 and 300 patien...Continue Reading

References

Jan 1, 1992·Journal of Cardiovascular Pharmacology·R van der DoesB Ehmer
Jan 1, 1987·Drugs·R Berlin
Jan 1, 1997·European Journal of Clinical Pharmacology·U Hauf-ZachariouE Pfarr
Sep 19, 1964·British Medical Journal·S C SRIVASTAVAD J NEWELL
Jan 27, 2005·The American Journal of Cardiology·Michel F RousseauAndrew A Wolff
Oct 11, 2005·European Heart Journal·Jean-Claude TardifUNKNOWN INITIATIVE Investigators
Apr 28, 2006·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·J P Vilaine

❮ Previous
Next ❯

Citations

Jan 8, 2019·European Heart Journal·Thomas F Lüscher
Apr 19, 2019·European Heart Journal Supplements : Journal of the European Society of Cardiology·Roberto FerrariCristina Balla
Mar 11, 2020·European Heart Journal. Cardiovascular Pharmacotherapy·Roberto Ferrari, Giuseppe Rosano
May 21, 2020·Cardiology and Therapy·Maria G GlezerUNKNOWN ODA investigators
Aug 28, 2020·Molecular and Cellular Biochemistry·Muhammad Afzal
Aug 11, 2019·Current Topics in Medicinal Chemistry·Yue ZhouKun Sun
Nov 19, 2019·European Heart Journal Supplements : Journal of the European Society of Cardiology·Roberto FerrariA Squeri
Dec 14, 2019·Indian Journal of Pharmacology·Lamiaa Ahmed Ahmed
Dec 29, 2020·European Heart Journal·Allan DaviesThomas F Lüscher
Nov 15, 2020·European Heart Journal·Roberto FerrariPaolo Cimaglia
Jul 9, 2021·Nature Reviews. Cardiology·Edoardo BerteroChristoph Maack
Jul 22, 2021·The FEBS Journal·Ling WuLiang Zhao
Nov 19, 2021·Expert Opinion on Pharmacotherapy·Jayakumar SreenivasanWilbert S Aronow

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.